Browsing Tag
T-MAXIMUM Pharmaceutical
1 post
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.